RS65359B1 - Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja - Google Patents
Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanjaInfo
- Publication number
- RS65359B1 RS65359B1 RS20240380A RSP20240380A RS65359B1 RS 65359 B1 RS65359 B1 RS 65359B1 RS 20240380 A RS20240380 A RS 20240380A RS P20240380 A RSP20240380 A RS P20240380A RS 65359 B1 RS65359 B1 RS 65359B1
- Authority
- RS
- Serbia
- Prior art keywords
- pharmaceutical composition
- treatment
- htbz
- use according
- hours
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| EP21178882.3A EP3936130B1 (en) | 2014-05-06 | 2015-05-06 | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65359B1 true RS65359B1 (sr) | 2024-04-30 |
Family
ID=53264772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240380A RS65359B1 (sr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
| RS20220008A RS62782B1 (sr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220008A RS62782B1 (sr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20170071932A1 (enExample) |
| EP (3) | EP3139925B1 (enExample) |
| JP (4) | JP6635945B2 (enExample) |
| KR (5) | KR20200133003A (enExample) |
| CN (3) | CN106456629A (enExample) |
| AU (1) | AU2015256012B2 (enExample) |
| CA (1) | CA2947736C (enExample) |
| CY (1) | CY1125058T1 (enExample) |
| DK (2) | DK3139925T3 (enExample) |
| ES (2) | ES2976207T3 (enExample) |
| FI (1) | FI3936130T3 (enExample) |
| HR (2) | HRP20220025T1 (enExample) |
| HU (2) | HUE057839T2 (enExample) |
| IL (1) | IL248745B (enExample) |
| LT (2) | LT3139925T (enExample) |
| MX (1) | MX387625B (enExample) |
| NZ (1) | NZ725826A (enExample) |
| PL (2) | PL3936130T3 (enExample) |
| PT (2) | PT3936130T (enExample) |
| RS (2) | RS65359B1 (enExample) |
| RU (1) | RU2753740C2 (enExample) |
| SI (2) | SI3139925T1 (enExample) |
| SM (2) | SMT202200193T1 (enExample) |
| WO (1) | WO2015171802A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2018000121A1 (en) | 2015-10-30 | 2019-10-04 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| US10442800B2 (en) | 2016-06-29 | 2019-10-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of NBI-98854, preparation method and use thereof |
| TW202515564A (zh) * | 2016-12-02 | 2025-04-16 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| WO2018130345A1 (en) | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| JP2020508337A (ja) | 2017-02-27 | 2020-03-19 | サンド・アクチエンゲゼルシヤフト | バルベナジン塩の結晶形態 |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| EP3606529A1 (en) * | 2017-04-01 | 2020-02-12 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JP7250692B2 (ja) * | 2017-04-01 | 2023-04-03 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療における使用のためのジヒドロテトラベナジン |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| WO2018200605A1 (en) * | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| US20200276184A1 (en) | 2017-09-21 | 2020-09-03 | Neurocrine Biosciences, Inc. | High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| EA202090932A1 (ru) | 2017-10-10 | 2021-05-20 | Нейрокрин Байосайенсиз, Инк | Способы введения некоторых vmat2-ингибиторов |
| JP2021503009A (ja) * | 2017-11-08 | 2021-02-04 | フォアシー ファーマシューティカルズ シーオー．，リミテッド | ジヒドロテトラベナジンのエステル |
| CN110621674B (zh) | 2017-12-26 | 2022-03-29 | 苏州科睿思制药有限公司 | 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途 |
| DK3784237T3 (da) * | 2018-04-25 | 2024-01-08 | Shinkei Therapeutics Inc | Indretning til transdermal levering af tetrabenazin |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| AU2019287524A1 (en) | 2018-06-14 | 2020-12-24 | Neurocrine Biosciences, Inc. | VMAT2 inhibitor compounds, compositions, and methods relating thereto |
| JP2021528481A (ja) | 2018-08-15 | 2021-10-21 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２阻害剤を投与するための方法 |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| JOP20210274A1 (ar) * | 2019-05-09 | 2023-01-30 | Neurocrine Biosciences Inc | طرق لإعطاء مثبط vmat2 معين |
| US10940141B1 (en) * | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081929B1 (en) * | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| JP2010509336A (ja) * | 2006-11-09 | 2010-03-25 | ニューヨーク ユニバーシティ | サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| SI3061760T1 (en) | 2008-09-18 | 2018-04-30 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| EP2576552A4 (en) * | 2010-06-01 | 2013-11-13 | Aupex Pharmaceutical Inc | BENZOQUINOLONE INHIBITORS OF VMAT2 |
| EP4345100A3 (en) * | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP6718376B2 (ja) * | 2014-02-07 | 2020-07-08 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
-
2015
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS65359B1 (sr) | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja | |
| Berk et al. | N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial | |
| HK40111840A (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK40067005B (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK1235303A1 (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK1235303B (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK40067005A (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| EP4082549A1 (en) | Drug for preventing dialysis shift or renal death | |
| US20250281499A1 (en) | Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain | |
| US20250281500A1 (en) | Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease | |
| US20250281498A1 (en) | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies | |
| Chaplin et al. | Drug points: Second‐generation antipsychotics | |
| Schmidt et al. | P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia | |
| KR101432905B1 (ko) | 다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물 | |
| HK40112908A (zh) | 重症疟疾和无并发症疟疾的治疗 | |
| US20080070952A1 (en) | Inhibition or Treatment of Dyskinesia | |
| Vinall | Update on Safety Issues in the Treatment of Rheumatic Diseases. | |
| JP2021522177A (ja) | イオン輸送体の活性を増強するための組成物および方法ならびにその使用 |